the results suggest that the thromboxane synthetase inhibitor , cgs 12970 , when administered in the subacute phase of recovery from myocardial infarction , does not protect against the induction of ventricular tachycardia by programmed electrical stimulation or the spontaneous development of ventricular fibrillation in the postinfarcted canine heart .
C0027051
myocardial
C0018787
heart